3SBio Reports Phase II Lung Cancer Data for Tivunatamig
3SBio reported Phase II results showing median progression-free survival of 13.6 to 13.8 months in first-line advanced lung cancer treatment.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, which relied on a 3SBio press release distributed by PR Newswire, tivunatamig (PF-08634404/SSGJ-707) combined with chemotherapy produced median progression-free survival of 13.6 months in squamous tumors and 13.8 months in non-squamous tumors. Objective response rates reached 80.7% and 77.5%, compared with 67.7% and 44.7% in control groups. The company said its safety profile was broadly comparable to the control therapy.
Pfizer licensed the drug in 2025. The study covers first-line treatment of advanced non-small cell lung cancer.
why it matters
For the broader market, this is mainly news about a biotech company and its partner. The Phase II figures are interim, and the Phase III result will be the key test. Investor interest in 3SBio and Pfizer shares will likely depend on whether these findings hold up in larger trials.
tags
instruments
sources
- 3SBio Inc. Posts Phase II NSCLC Data: mPFS ~13.6–13.8 Months — TradingView, 28 October 2026 at 12:56 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗